Video: Hope & Breakthroughs: 2025 ASCO Updates for Small Cell Lung Cancer

What’s new in the fight against small cell lung cancer? A lot. Our 2025 ASCO SCLC Scholars share key highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting—straight from the patient advocate perspective.

Topics include:

• FORTÉ Trial: A new approach to first-line treatment for extensive-stage SCLC

• DELFI Study: Advancing second-line options with innovative immunotherapy

• ZL-1310: A new antibody-drug conjugate showing exciting early results

• Emerging treatments for patients with brain metastases

• Poster sessions and one-on-one conversations with researchers and oncologists

• Firsthand insights into what it’s like to participate in a clinical trial

These first-time ASCO attendees share how this experience reshaped their understanding of advocacy, science, and survival.

Mark your calendar: Join us on Wednesday, July 9 at 7 PM ET for our next LiveLung SCLC meeting featuring Dr. Neal Ready, medical oncologist from Duke Cancer Institute.

Registration link: https://www.livelung.org/meetings/sclc

If you have been impacted by lung cancer, we invite you to join us at one of our virtual or in-person meetings. Visit https://www.livelung.org/meetings to learn more and find a meeting near you!

Subscribe to our YouTube channel and click the notification bell so you know when new educational lung cancer videos are available https://www.youtube.com/livelung

This video content has been made available for informational and educational purposes only. The Video Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read or seen on the Site.

LiveLung and speakers hereby disclaim any and all liability to any party for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising directly or indirectly from any use of the Video Content, which is provided as is, and without warranties.